Endometrial clinical trials: recruitment closed
ENGOT-en7 / AtTEnd | MaNGO Study |
STATUS: Recruitment completed
SPONSOR: Mario Negri Institute for Pharmacological Research (IRFMN)
LEAD GROUP: MaNGO
ENGOT Model: A
TITLE: Atezolizumab Trial in Endometrial cancer. Phase III double-blind randomized placebo controlled trial of Atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer
ClinicalTrials.gov ID: NCT03603184
MaNGO sites (click to see the list on clinicaltrials.gov)
Sinossi (click to see pdf)
Updates (click to see the Newsletter)
ESMO 2023 (click to see the abstract)
ENGOT-en15 / GOG-3064
STATUS: Recruitment completed
SPONSOR: Merck Sharp & Dohme LLC
LEAD GROUP: MITO
ENGOT Model: C
TITLE: A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
ClinicalTrials.gov ID: NCT05173987
MaNGO sites (click to see the list)